PDE5A and inflammatory bowel disease: More importantly, randomized controlled trials should systematically assess the synergistic effects and safety of combined PDE5 inhibitors and anti-inflammatory therapies, while also paying attention to the potential impacts of various IBD drugs themselves on the gonadal axis and mood, to comprehensively weigh benefits against risks.